Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantheus Holdings
(NQ:
LNTH
)
95.92
+1.01 (+1.06%)
Streaming Delayed Price
Updated: 12:39 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lantheus Holdings
< Previous
1
2
3
Next >
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
August 03, 2023
Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readiness
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
July 20, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
June 12, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
May 23, 2023
PYLARIFY success leads to maximum payment in first year
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports First Quarter 2023 Financial Results
May 04, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
April 24, 2023
From
Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
Via
GlobeNewswire
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
April 20, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Two Key Executive Promotions
March 17, 2023
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Are These Medical Device Makers Getting Ready To Rally?
March 10, 2023
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.
Via
MarketBeat
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
February 16, 2023
Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2022 Earnings Conference Call and Webcast on February 23, 2023, at 8:00 a.m. Eastern Time
February 09, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
February 08, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s Disease
February 06, 2023
MK-6240 is an F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer’s Disease
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the J.P. Morgan 2023 Healthcare Conference
January 04, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Closing of Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 with POINT Biopharma
December 20, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform
December 12, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Holdings, Inc. Announces Pricing of Offering of $500 Million Convertible Senior Notes due 2027
December 06, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Holdings, Inc. Announces Proposed Offering of $500 Million Convertible Senior Notes due 2027
December 05, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Appointment of Amanda Morgan as Senior Vice President, Commercial
November 29, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA
November 28, 2022
DEFINITY is the leading diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003
November 14, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
S&P 500 Component DexCom Set For Further Price, Earnings Growth
November 13, 2022
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Lantheus to Present at the Jefferies London Healthcare Conference
November 09, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
MarketBeat: Week in Review 10/24-10/28
October 29, 2022
Stocks finished the week on a bullish note, and the MarketBeat analysts continue to guide you to the stocks and stories that are moving the market
Via
MarketBeat
Topics
Economy
Electric Vehicles
Exposures
Economy
Electric Vehicles
Interest Rates
Can Mid-Cap Lantheus Continue its 2022 Outperformance?
October 28, 2022
Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test.
Via
MarketBeat
Topics
ETFs
Initial Public Offering
Exposures
Securities Market
Lantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern Time
October 20, 2022
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.